Why GLP-1 Alone Is Not Enough for Addiction Recovery

Medically Reviewed by Dr. Kenneth Spielvogel, MD, Senior Medical Officer at Carrara Treatment

Is a GLP-1 medication alone sufficient for lasting addiction recovery? While GLP-1 receptor agonists like semaglutide effectively reduce physical cravings, they do not resolve the psychological trauma, behavioral patterns, or social disconnection that drive addictive behavior. Lasting sobriety requires an integrated program combining metabolic therapy with intensive clinical care, somatic trauma healing, and physical restoration.

Key Takeaways

• Quieting Cravings is Only Step One: GLP-1 medications effectively quieten the constant physical urge to use, but they do not teach the cognitive coping skills necessary to handle life’s stressors.
• The Biopsychosocial Reality: Addiction is a complex biological, psychological, and social disease. Medication only addresses the biological component, leaving psychological and social roots untouched.
• Superiority of Combined Care: Large-scale clinical meta-analyses demonstrate that combining pharmacotherapy with structured behavioral therapy is significantly more effective than medication alone.
• Trauma and Somatic Healing: Addictive behaviors are often adaptive responses to unresolved trauma. Lasting recovery requires bottom-up somatic therapy to release stress stored in the nervous system.
• The Carrara Model: At Carrara, GLP-1 therapy is seamlessly integrated into a premium, four-stage protocol that optimizes metabolic, neurological, psychological, and physical health.

The Breakthrough of GLP-1 Medications in Addiction Medicine

The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, has been hailed as one of the most exciting breakthroughs in modern addiction psychiatry. Originally developed to treat type 2 diabetes and obesity, these medications have shown a remarkable ability to target the brain’s core reward pathways, specifically the ventral tegmental area and the nucleus accumbens [1].

By modulating dopamine signaling, GLP-1 medications effectively blunt the artificial reward signals triggered by addictive substances, quietening the intrusive, obsessive “drug noise” that makes early sobriety so challenging [1]. Large-scale clinical database studies from 2024 to 2026 have documented dramatic reductions in alcohol intoxication, opioid overdoses, and stimulant use among individuals taking these medications [2] [3] [4].

It is important to note that GLP-1 receptor agonists are not currently FDA-approved for the treatment of any substance use disorder; their use in addiction medicine is strictly off-label and requires direct physician oversight [1]. However, as these medications grow in popularity, a dangerous misconception has emerged: the belief that a weekly injection can serve as a standalone “cure” for addiction. In the clinical community, there is a clear consensus that while these medications are invaluable tools, “a pill is never the program” [1].

The Biopsychosocial Model: Why Medication Only Solves Part of the Equation

To understand why a medication alone cannot sustain long-term recovery, it is necessary to view addiction through the lens of the biopsychosocial model [5]. This widely accepted clinical framework recognizes that substance use disorders are not simple chemical imbalances; they are complex, multifaceted conditions driven by three overlapping dimensions of human health.

The Biological Dimension

This is where GLP-1 medications excel. They stabilize blood sugar, improve metabolic health, and regulate the hyperactive dopamine pathways that drive physical cravings and compulsive reward-seeking [1]. However, biology is only one-third of the recovery equation.

The Psychological Dimension

Addictive behavior is rarely just about the drug; it is almost always an adaptive response to underlying psychological pain, shame, depression, anxiety, or unresolved trauma. A weekly injection of semaglutide cannot resolve a client’s deep-seated trauma, reframe negative thought patterns, or heal the emotional wounds of childhood neglect. Without intensive, evidence-based psychotherapy, the psychological drivers of addiction remain fully intact, waiting to resurface when the medication is paused or when life presents an overwhelming emotional trigger. Effective relapse prevention strategies must address these deeper psychological roots.

The Social and Environmental Dimension

Addiction thrives in isolation and is heavily influenced by a client’s environment, relationships, and daily routines. GLP-1 medications do not repair broken marriages, rebuild professional careers, or teach clients how to establish healthy boundaries with enabling friends. Long-term recovery requires a supportive community, a safe living environment, and a profound sense of purpose and meaning, none of which can be prescribed in a syringe.

Dimension of Addiction	Primary Drivers	Treatment Intervention
Biological	Dopamine dysfunction, physical cravings, metabolic instability.	GLP-1 therapy, medical detox, clinical nutraceuticals.
Psychological	Trauma, shame, negative cognitive patterns, emotional dysregulation.	Cognitive Behavioral Therapy (CBT), DBT, Somatic Experiencing.
Social / Environmental	Isolation, toxic relationships, lack of purpose, environmental triggers.	Community integration, family therapy, lifestyle redesign.

What the Research Shows: The Superiority of Combined Treatment

The clinical necessity of combining medication with behavioral therapy is supported by decades of robust scientific research.

A landmark systematic review and meta-analysis published in JAMA Network Open in 2020 analyzed 30 unique randomized clinical trials examining the combination of Cognitive Behavioral Therapy (CBT) and pharmacotherapy for substance use disorders [6]. The meta-analysis, which included data from trials targeting alcohol, cocaine, and opioids, found that combined CBT and pharmacotherapy was significantly more effective at reducing substance use frequency and quantity compared to usual clinical management and medication alone [6].

The researchers concluded that best practices in addiction medicine must include pharmacotherapy plus structured, evidence-based behavioral therapy, rather than relying on medication combined with nonspecific counseling or minimal clinical management [6].

Furthermore, the National Institute on Drug Abuse (NIDA) estimates that the relapse rate for substance use disorders is between 40% and 60% [7]. This high rate of relapse highlights the reality that simply stopping substance use temporarily is not enough; individuals must actively learn new cognitive and behavioral strategies to manage stress, navigate high-risk situations, and prevent the “abstinence violation effect” from turning a minor slip into a full-scale relapse.

Addressing the Root Cause: Trauma and Somatic Nervous System Regulation

At Carrara Treatment, we believe that addiction is not a moral failing or a simple disease of willpower; it is a symptom of a dysregulated nervous system, often rooted in trauma. When an individual experiences trauma, the survival energy of that event can become trapped in the body, leaving the autonomic nervous system stuck in a chronic state of hypervigilance or shutdown. Substances are often used as an external tool to self-medicate this painful, internal state of physical dysregulation.

While top-down cognitive therapies like CBT are invaluable, they are often insufficient on their own because trauma is stored in the body’s deeper, non-verbal structures. To truly heal, clients must engage in bottom-up therapies, such as Somatic Experiencing and body-oriented trauma work [8].

Somatic therapy allows clients to gently release the trapped survival energy, restoring natural balance and resilience to the autonomic nervous system [8]. When combined with the craving-reduction properties of GLP-1 medications, somatic trauma work is exceptionally powerful. By quietening the physical roar of cravings, the medication provides clients with the calm, stable baseline necessary to safely access and heal their deepest trauma without becoming overwhelmed or triggered.

The Carrara Approach: A Multidimensional Model for Lasting Recovery

Under the direction of Dr. Kenneth Spielvogel, MD, Senior Medical Officer, Carrara Treatment has developed a sophisticated, luxury program that bridges Tier-1 hospital clinical standards with a five-star hospitality model. We do not view GLP-1 medications as a standalone cure, but as a vital component of our comprehensive, four-stage integration protocol within our clinical medical program:

1. Stage 1: Stabilization (Weeks 0–4): The immediate priority is safe, comfortable medical detoxification and acute stabilization [1]. We utilize standard, evidence-based medications alongside targeted clinical nutraceuticals (such as N-acetylcysteine, magnesium, and high-dose omega-3 fatty acids) to calm the nervous system and protect cellular health [1].
2. Stage 2: Metabolic Repair (Weeks 2–12): Once acute withdrawal has resolved, we introduce low-dose GLP-1 therapy to target persistent cravings and stabilize metabolic function [1]. This clinical window of calm allows clients to engage deeply in intensive psychotherapy, somatic trauma healing, and dialectical behavior therapy (DBT) [1].
3. Stage 3: Regeneration (Months 3–6): We focus on rebuilding physical resilience and restoring autonomic nervous system balance through progressive strength training, cold contrast therapy, infrared sauna sessions, and biofeedback-guided breathwork [1]. Recent 2024-2025 clinical reviews confirm that structured exercise significantly reduces cravings, alleviates anxiety and depression, and accelerates brain repair [9] [10].
4. Stage 4: Longevity and Thriving (Beyond 6 Months): We optimize long-term hormonal, cardiovascular, and nutritional health, ensuring that our clients have the physical vitality, emotional resilience, and supportive community to sustain a vibrant, purposeful life in long-term recovery [1].

“At Carrara, we believe GLP-1 medications may represent one of the most important breakthroughs in addiction medicine in decades, not simply because they can reduce appetite, but because many patients report a meaningful reduction in cravings, compulsive reward-seeking, and the constant ‘mental noise’ surrounding alcohol, food, and other substances. We are seeing emerging evidence, supported by growing clinical experience, that these medications may help regulate the same reward and dopamine pathways that drive addictive behavior.”

“That said, we do not view GLP-1s as a standalone cure. At Carrara, they are integrated into a broader recovery and resilience model that includes exercise, metabolic optimization, behavioral treatment, nutrition, sleep, nervous system regulation, and long-term rebuilding of both physical and mental health.”

— Dr. Kenneth Spielvogel, MD, Senior Medical Officer, Carrara Treatment

Begin Your Integrated Recovery Today

If you or a loved one is ready to break the cycle of addiction and rebuild your life from the inside out, GLP-1 therapy combined with Carrara’s comprehensive clinical care may represent the turning point you have been searching for. Learn more about our treatment philosophy and how we approach recovery differently.

To determine candidacy, our medical team conducts a comprehensive clinical evaluation, including detailed metabolic laboratory work, cardiovascular assessments, and psychiatric screenings.

For a confidential conversation about our premium, integrated treatment programs, call (888) 383-5207.

Frequently Asked Questions

Why is a GLP-1 medication alone insufficient for long-term addiction recovery?

A GLP-1 medication is a powerful physiological tool that quietens physical cravings and “drug noise,” but it cannot heal the psychological wounds, trauma, shame, or behavioral patterns that drive addictive behavior. Without intensive psychotherapy, somatic healing, and lifestyle rebuilding, the risk of relapse remains high once the medication is discontinued.

What therapies are combined with GLP-1 treatment at Carrara?

At Carrara Treatment, we integrate medically supervised GLP-1 therapy with a comprehensive suite of elite clinical care. This includes cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), trauma-informed Somatic Experiencing, progressive strength training, cold contrast therapy, and personalized nutritional restoration.

What happens to cravings if I stop taking GLP-1 medications?

If GLP-1 medications are discontinued without establishing a strong foundation of psychological resilience and behavioral coping mechanisms, physical cravings and intrusive thoughts are highly likely to return. Carrara’s four-stage integration protocol focuses on rebuilding long-term autonomic balance so clients can sustain vibrant, drug-free lives.

References

[1] Carrara Treatment. GLP-1 Medications for Addiction Treatment: What the Research Shows and How Carrara Is Leading. Available at: https://carraratreatment.com/glp-1-addiction-treatment/.

[2] Wang W, Volkow ND, Wang Q, et al. Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder. JAMA Network Open. 2024;7(9):e2435247. doi:10.1001/jamanetworkopen.2024.35247.

[3] Qeadan F, McCunn A, Tingey B. The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis. Addiction. 2025;120(2):236-250. doi:10.1111/add.16679.

[4] Cai M, Choi T, Xie Y, Al-Aly Z. GLP-1RA and risks of substance use disorders among US veterans with type 2 diabetes: A cohort study. The BMJ. 2026;392:e086886. doi:10.1136/bmj-2025-086886.

[5] Wangensteen T. A Comprehensive Approach to Understanding Substance Use Disorders as a Biopsychosocial Disorder. Frontiers in Psychiatry. 2021;12:839187. doi:10.3389/fpsyt.2021.839187.

[6] Ray LA, Meredith LR, Kiluk BD, et al. Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis. JAMA Network Open. 2020;3(6):e208279. doi:10.1001/jamanetworkopen.2020.8279.

[7] National Institute on Drug Abuse. Drugs, Brains, and Behavior: The Science of Addiction. Relapse Rates in Addiction Recovery. Available at: https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction.

[8] Kuhfuß M, Maldei T, Walter R, et al. Somatic experiencing – effectiveness and key factors of a body-oriented trauma therapy: a scoping literature review. European Journal of Psychotraumatology. 2021;12(1):1929023. doi:10.1080/20008198.2021.1929023.

[9] Frontiers in Psychology. Effect of physical exercise on the emotional and cognitive levels of patients with substance use disorder. Frontiers in Psychology. 2024;15:1348224. doi:10.3389/fpsyg.2024.1348224.

[10] National Institutes of Health. A Review of Exercise Interventions for Rehabilitation in Drug Addiction. PMC. December 10, 2025. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12692742/.